This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: G12.21 | Special Copayment Reduction: V123 | Coverage period: 5 years |
| B. Synonyms | Lou Gehrig disease, Sporadic ALS, Motor neuron disease (MND), Sporadic amyotrophic lateral sclerosis |
| C. Adult onset | Very high likelihood of first presenting in adulthood — mean age of onset 55–65 years; lifetime risk about 1:400 |
| 1. History | Described by Charcot in 1869; became known to the public through the case of Lou Gehrig in 1939; reclassified as sporadic form with discovery of C9orf72 in 2011 |
| 2. Causes | Cause unknown in most; combined genetic and environmental factors; TDP-43 pathology is the common final pathway in ~97% |
| 3. Genetics | Sporadic, but de novo variants or low-penetrance variants in a minority; polygenic risk scores under study |
| 4. General epidemiology | Prevalence 4–6 per 100,000; about 90% of all ALS; annual incidence 2–3 per 100,000 |
| 5. Pathophysiology | Combined mechanisms of TDP-43 aggregation, RNA processing impairment, excitotoxicity, neuroinflammation, and axonal transport impairment |
| 6. Symptoms | Progressive limb weakness, dysarthria/dysphagia, respiratory failure; sensation remains normal |
| 7. Signs | Mixed upper and lower motor neuron signs, fasciculations, tongue atrophy, positive Babinski |
| 8. Screening | Currently no population screening; plasma NfL under study as a biomarker |
| 9. Diagnosis | Gold Coast/El Escorial criteria, EMG, gene panel, NfL biomarker |
| 10. Treatment | Riluzole and edaravone standard treatment; AMX0035 (phenylbutyrate + ursodoxicoltaurine); multidisciplinary supportive care |
| 11. Prognosis | Median survival 2–3 years after diagnosis; 5-year survival about 10–20% |
| 12. Prevention | No established prevention; risk factor management (avoid smoking, minimize toxic exposure) |
| 13. References | Hardiman O et al. Nat Rev Dis Primers 2017, and 9 other papers |
The clinical description of amyotrophic lateral sclerosis (ALS) began in 1869, when Jean-Martin Charcot, called the father of French neurology, systematically compiled cases of progressive motor neuron paralysis accompanied by sclerosis of the lateral columns of the spinal cord. Through pathological dissection, Charcot showed that degeneration of both the corticospinal tracts (lateral columns) and the anterior horn cells coexists, defining the essential characteristic of ALS as simultaneous involvement of upper and lower motor neurons. In 1939, the American Major League Baseball player Lou Gehrig announced his retirement after an ALS diagnosis, and the disease became known to the public by the name "Lou Gehrig disease". In the late 20th century, the TDP-43 protein (2006) was discovered as the universal pathological protein of ALS, and in 2011 the C9orf72 repeat expansion was identified as a common genetic cause of ALS-FTD, broadening understanding of the ALS continuous spectrum. In terms of treatment, riluzole was approved in 1994 as the first disease-modifying drug, followed by edaravone (2017) and AMX0035 (2022). In sporadic ALS the genetic cause is unclear, making diagnosis and discovery of treatment targets difficult, but molecular understanding is advancing rapidly through large-scale GWAS and single-cell omics studies.
Sporadic ALS (sALS) accounts for about 90% of all ALS and is the form in which no clear genetic cause or single environmental cause has been identified. According to the multistep hypothesis, ALS develops when genetic vulnerability and environmental exposure act in combination and exceed a certain threshold, and it is proposed to pass through an average of 6 pre-onset steps. Environmental risk factors studied include exposure to heavy metals (lead, cadmium, mercury), organic pesticides (formaldehyde, dichlorodiphenyltrichloroethane), military service (especially Iraq war veterans), vigorous occupational physical activity, and electric shock, but a consistent causal relationship has not been established. Pathological redistribution of the TDP-43 (TARDBP gene product) protein from the nucleus to the cytoplasm and its insoluble aggregation is the common final pathology observed in about 97% of patients with sporadic ALS. Glutamate excitotoxicity (excess glutamate due to decreased EAAT2), oxidative stress, mitochondrial dysfunction, and neuroinflammation are also important contributing factors. Recently, epigenetic changes (DNA methylation, histone modification) and gut microbial imbalance (dysbiosis) have also emerged as new areas of research in ALS pathogenesis.
Sporadic ALS is by definition a form without a family history, but genetic factors are not completely excluded. In about 5–10% of patients with sporadic ALS, low-penetrance variants in ALS-related genes (including the C9orf72 repeat expansion) are found. This suggests that the boundary between sALS and FALS is not absolute. The C9orf72 repeat expansion is found in about 5–7% of ALS patients without a family history. Genome-wide association study (GWAS) studies have identified several common variant risk loci, including UNC13A, ERGIC1, TNIP1, and CAMTA1, but the effect size of each is small. Studies using a polygenic risk score have reported that differences in genetic risk between individuals are related to age of onset. De novo mutations are also proposed as a cause of some sALS, which explains in particular the occurrence of new mutations rather than inheritance from a spouse. The prion-like spreading hypothesis of TDP-43 is an attempt to explain at the molecular level the clinical observation that lesions spread to adjacent regions of the nervous system in sALS. Epigenome abnormalities and RNA editing impairment are also being studied as genome-level mechanisms contributing to the onset of sALS.
ALS is the most common motor neuron disease occurring in adults, with a prevalence of about 4–8 per 100,000 people and an annual incidence of about 1.5–3 per 100,000 people in Western countries. Sporadic ALS accounts for about 90% of all ALS. The mean age of onset is 55–65 years, and the lifetime risk in the entire population is about 1/400–1/500. It occurs about 1.3–1.5 times more frequently in men than in women, but the sex difference decreases in the elderly aged 65 and over. In a study based on Korean National Health Insurance data, the prevalence of ALS in Korea is estimated at about 3–4 per 100,000 people, and the number of patients is increasing as the country enters an aging society. Regionally, cases of clustered occurrence of the ALS-parkinsonism-dementia complex syndrome (Lytico-Bodig) in the past in Guam in the western Pacific (Chamorro population), the Kii Peninsula of Japan, and western New Guinea are known, but this regional clustering has now declined. The incidence of ALS peaks in the 60s and shows an inverted U-shaped pattern, declining after the 70s–80s. This is explained by survivor bias, in which individuals with a genetic predisposition to ALS have already developed disease or died of other causes.
The pathophysiology of sporadic ALS involves multiple interacting pathways that result in selective death of motor neurons. The most central molecular pathology is pathological change in the TDP-43 protein. TDP-43, which normally performs various RNA metabolism functions in the nucleus such as mRNA splicing, transcriptional regulation and stress granule formation, is redistributed from the nucleus to the cytoplasm in sALS and forms insoluble phosphorylated aggregates, resulting in loss of nuclear RNA processing function. This TDP-43 pathology is observed in about 97% of sALS patients. Glutamate excitotoxicity is a mechanism known from early on: reduced function of the astrocytic glutamate reuptake transporter (EAAT2) leads to excessive accumulation of synaptic glutamate, increasing NMDA receptor overactivation and calcium influx and inducing excitotoxic death of motor neurons. Mitochondrial dysfunction aggravates oxidative stress through insufficient energy supply and excessive production of reactive oxygen species (ROS). Impaired axonal transport disrupts the movement of mitochondria, neurotrophic factors and organelles between the cell body and the terminals, driving neurons into a state of energy deficiency and signaling impairment. Neuroinflammatory responses of microglia and astrocytes are also known to accelerate motor neuron death.
The clinical symptoms of sporadic ALS vary according to the site of onset and the pattern of progression. About 65–70% of cases begin with symptoms in the limbs (limb-onset), and about 25–30% begin with bulbar dysfunction (bulbar-onset). In the remaining minority, symptoms appear first in the thoracolumbar region or the respiratory muscles. The initial symptoms of limb-onset disease often begin with decline in fine hand function in one hand, such as difficulty grasping objects, inability to button clothes and difficulty using chopsticks, or with drooping of one foot (foot drop). The weakness then gradually spreads to both sides and to proximal muscles, causing gait disturbance, inability to climb stairs and inability to raise the arms. In bulbar-onset disease, slurred speech (dysarthria), difficulty swallowing food (dysphagia) and voice changes are the initial symptoms, accompanied by drooling and weight loss. Systemic symptoms include progressive muscle atrophy, muscle twitching due to fasciculations, muscle cramps, fatigue and dyspnea (beginning with nocturnal hypoventilation and worsening to progressive respiratory failure). In some C9orf72-associated sALS, symptoms of frontal lobe dysfunction (impaired impulse control, impaired judgment, reduced verbal fluency) may occur. Sensation, vision, hearing and bladder and rectal function are mostly preserved.
On physical examination, the key finding in ALS is the coexistence of signs of upper and lower motor neuron involvement. Signs due to lower motor neuron (anterior horn cells, brainstem motor nuclei) damage include muscle atrophy, fasciculations (especially of the tongue, deltoid and quadriceps), flaccid weakness, and decreased or absent deep tendon reflexes. Signs due to upper motor neuron (cortical motor neurons, corticospinal tract) damage include spasticity, hyperreflexia of the deep tendon reflexes, the Babinski sign (the big toe extends upward when the sole is scratched), the Hoffmann sign (hyperreflexia of the fingers) and an exaggerated jaw jerk. The paradoxical pattern in which both types of signs coexist in the same patient (e.g., coexistence of muscle atrophy and tendon hyperreflexia) is a unique characteristic of ALS. Tongue atrophy, tongue fasciculations and a diminished soft palate reflex are evidence of bulbar involvement. Emotional incontinence (inability to control laughing and crying) due to pseudobulbar affect is another sign of upper motor neuron involvement. On examination, increased use of accessory respiratory muscles, paradoxical breathing and decreased FVC in the supine position are early indicators of respiratory failure. Eye movements remain normal until the late stage, and there is no sensory abnormality.
At present there is no established population screening for sporadic ALS. This is because the prevalence of ALS is relatively low and specific biomarkers are not yet at the stage of clinical application. However, plasma and cerebrospinal fluid neurofilament light chain (NfL) and phosphorylated neurofilament heavy chain (pNfH) rise tens of times in ALS patients and are being validated as sensitive biomarkers of neurodegeneration. Plasma NfL rises even in the preclinical stage before diagnosis and correlates with the rate of disease progression and prognosis. The TDP-43 seed amplification assay (SAA) is a technique that sensitively detects pathological TDP-43 in cerebrospinal fluid and olfactory mucosa, and research is under way to improve antemortem diagnostic accuracy. Neurological assessment every six months and plasma NfL measurement are being explored in a research context as a follow-up protocol for high-risk groups for ALS (carriers of ALS-associated variants without a family history, occupational groups at high risk of developing ALS). For rapid diagnosis, a pathway-shortening protocol is recommended in which, when ALS is suspected, the patient is immediately referred to a specialized multidisciplinary team (ALS clinic) with the goal of confirming the diagnosis within the initial evaluation.
The diagnosis of ALS is made by integrating clinical criteria, electrophysiological testing, imaging and biomarkers. The most widely used clinical diagnostic criteria were the revised El Escorial criteria (Airlie House, 1998), but the more sensitive Gold Coast criteria (2020) are now used for clinical and research purposes. The Gold Coast criteria define clinically definite ALS as (1) coexistence of upper and lower motor neuron signs in the same body region, or (2) a progressively spreading pure lower motor neuron syndrome, and have high sensitivity. Nerve conduction studies (NCS) and electromyography (EMG) are essential for confirming lower motor neuron lesions in multiple body regions (cervical, thoracic, lumbosacral, bulbar). Brain and cervical spine MRI are used to exclude ALS mimics (cervical myelopathy, tumor, inflammation). On blood tests, elevated plasma NfL is used as a diagnostic aid and for monitoring the course. Genetic panel testing should be considered in all ALS patients, and panel testing that includes the C9orf72 repeat expansion and the major ALS genes is recommended even in sporadic patients. Muscle biopsy is not usually required but is performed when differentiation from muscle disease such as myositis is needed. The average diagnostic delay is known to be about 12–18 months after symptom onset, so improving the pathway to early diagnosis is an important clinical task.
Treatment of sporadic ALS consists of disease-modifying therapy and comprehensive supportive care. Among disease-modifying drugs, first, riluzole (Rilutek 50 mg orally twice daily) is the standard treatment and extends survival by about 2–3 months by inhibiting glutamate toxicity. Second, edaravone (Radicava) is a free radical scavenger that suppresses oxidative stress, and an effect of slowing functional decline has been confirmed in some patient groups. Third, AMX0035 (sodium phenylbutyrate + ursodeoxycholic acid; Relyvrio) simultaneously targets endoplasmic reticulum stress and mitochondrial dysfunction and received FDA approval in 2022, but the effect was not reproduced in the subsequent confirmatory trial (PHOENIX trial), and it was voluntarily withdrawn (2024). A multidisciplinary team approach is essential for supportive care: respiratory management (NIV, BiPAP, tracheostomy ventilation in some cases), nutritional management (swallowing evaluation, nasogastric tube or gastrostomy), exercise and rehabilitation (physical therapy, occupational therapy), speech therapy, communication aids (eye-tracking AAC), palliative care (management of pain, secretions and cramps) and psychosocial support. Providing opportunities to access new therapies through participation in clinical trials is also an important element of the current ALS treatment strategy.
Sporadic ALS is a progressive fatal disease that is incurable to date, and the median survival after diagnosis is about 2–3 years. The 5-year survival rate is about 10–20%, and "long-term survivors" who live more than 10 years account for less than about 5% of all patients. Factors affecting prognosis include site of onset (bulbar-onset is worse than limb-onset; median survival about 1.5–2 years vs 2–3 years), age at onset (older onset is worse), FVC (forced vital capacity) at diagnosis, duration of diagnostic delay, initial ALSFRS-R functional score and its rate of decline, and baseline plasma NfL. Early application of noninvasive ventilation can extend median survival by about 7–12 months. Maintaining nutritional status (target BMI of 25 or higher) is also significantly associated with survival. Most deaths are due to respiratory failure. Patients treated at specialized multidisciplinary ALS clinics have been reported to survive about 7–9 months longer than those at general medical institutions, which emphasizes the importance of a specialized care system. In terms of quality of life, cognitive function and sensation are preserved until the late stage, so autonomy can be maintained through communication aids and environmental control devices.
At present there is no established method of preventing the primary onset of sporadic ALS. However, minimizing known environmental risk factors is recommended. Smoking has been identified in several epidemiological studies as an independent risk factor for ALS, and smoking cessation is the most important lifestyle prevention strategy. In occupational groups with high exposure to heavy metals (lead, mercury, cadmium) and organic pesticides, wearing appropriate protective equipment and minimizing exposure are recommended. There is some evidence that prevention of head trauma (prevention of sports injuries, wearing safety equipment) may also be associated with reduced ALS risk. Some studies show that strenuous physical activity increases ALS risk, but appropriate aerobic exercise has a general neuroprotective effect, so a balanced interpretation is needed. In terms of secondary prevention (early diagnosis and prevention of functional decline), early confirmation of diagnosis at a specialized ALS clinic early after symptom onset, early initiation of riluzole, regular pulmonary function assessment, nutritional management and rehabilitation interventions contribute to slowing the rate of functional decline and maintaining quality of life. Participation in clinical research contributes to the development of new treatments and also gives patients access to the latest therapies.